Eli Lilly is a safer way to capitalize on AI-driven drug discovery.

We recently published 10 Stocks With Massive Gains; 5 at Record Highs. Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) was one ...

Recursion Pharmaceuticals Inc. (NASDAQ:RXRX) is one of the AI stocks under $20 to buy now. On December 8, Recursion ...

Recursion (Nasdaq: RXRX), a leading clinical stage TechBio company decoding biology to radically improve lives, announced today its CEO & President, Najat Khan, Ph.D., will present Tuesday, January 13 ...

Recursion Pharmaceuticals Inc has faced significant challenges in its financial performance, highlighted by a sharp decline in revenue growth, which fell to -32.98% in Q3 2025 from +30.14% in Q2 2025.

This week, I had to make one of the most difficult decisions of my career: saying goodbye to 20% of the team at Recursion. The process was extraordinarily painful, and the costs were heartbreakingly ...

Recursion's share price has dropped in recent weeks due to poor clinical trial data, but its most mature assets are not reflective of its current capabilities. Recursion probably needs to advance 5-10 ...

Nvidia’s forthright ambitions to expand its drug development footprint are coming into focus, with the global computing powerhouse announcing a trio of new initiatives including a new collaboration ...

When you purchase through links on our site, we may earn an affiliate commission. Here’s how it works. The opportunity to explore a multi-genre universe in innovative ways is extremely exciting. Matt ...